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Positron emission tomographyDiverse age-associated neurodegenerative disorders are featured at a molecular level by depositions of self-
aggregatingmolecules, as represented by amyloid β peptides (Aβ) and tau proteins in Alzheimer's disease, and
cascade-type chain reactions are supposedly commenced with biochemical aberrancies of these amyloido-
genic components. Mutagenesis and multiplication of the genes encoding Aβ, tau and other pathogenic
initiators may accelerate the incipient process at the cascade top, rationalizing generations of transgenic and
knock-in animal models of these illnesses. Meanwhile, these genetic manipulations do not necessarily
compress the timelines of crucial intermediate events linking amyloidogenesis and neuronal lethality,
resulting in an incomplete recapitulation of the diseases. Requirements for modeling the entire cascade can be
illustrated by a side-by-side comparison of humans and animal models with the aid of imaging-based
biomarkers commonly applicable to different species. Notably, key components in a highly reactive state are
assayable by probe-assisted neuroimaging techniques exempliﬁed by positron emission tomography (PET),
providing critical information on the in-vivo accessibility of these target molecules. In fact, multispecies PET
studies in conjunction with biochemical, electrophysiological and neuropathological tests have revealed
putative neurotoxic subspecies of Aβ assemblies, translocator proteins accumulating in aggressive but not
neuroprotective microglia, and functionally active neuroreceptors available to endogenous neurotransmitters
and exogenous agonistic ligands. Bidirectional translational studies between human cases and model strains
based on this experimental paradigm are presently aimed at clarifying the tau pathogenesis, and would be
expanded to analyses of disrupted calcium homeostasis and mitochondrial impairments. Since reciprocal
causalities among the key processes have indicated an architectural interchangeability between cascade and
network connections as an etiological representation, longitudinal imaging assays with manifold probes
covering the cascade from top to bottom virtually delineate the network dynamics continuously altering in the
course of the disease and its treatment, and therefore expedite the evaluation and optimization of therapeutic
strategies intended for suppressing the neurodegenerative pathway over its full length.ational Institute of Radiological
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ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Imaging pathogenic cascade: a multistep link between the gain
of neurotoxicity and loss of neuronal integrity
Aging is a prime risk factor in the etiology of Alzheimer's disease
(AD) and diverse allied dementing illnesses. The fact that few
nonhuman species exhibit histopathological and phenotypic features
of neurodegenerative dementias [1–3] implies that the pathogenetic
mechanisms in these disorders unfold in a slow, gradual process
beyond the lifespan of such organisms. While rodents do not fully
model a chronological compression of human aging, genetic engi-
neering techniques allow them to start their lives at a prodromal stageof the disease, skipping a nonpathological preincubation period. A
simple methodology in this gene manipulation is to transgenically
overexpress pathogenic candidates known to accumulate in diseased
brains [4]. In AD, two major hallmark lesions, senile plaques and
neuroﬁbrillary tangles, are extracellular and intraneuronal aggregates
of amyloid b peptide (Aβ) and tau protein, respectively, and thus it is
feasible to conceive of them as molecular culprits responsible for the
initiation of the disease processes [5]. This view has been supported
by the discoveries of familial AD mutations in the genes coding amy-
loid precursor protein, presenilin-1 (PS-1) and presenilin-2 [6–10], as
all of these genetic defects result in an overproduction of either total
Aβ or relatively ﬁbrillogenic subspecies of Aβ termed Aβ42. Likewise,
mutations in the tau gene have been causally implicated in a class of
hereditary non-AD neurodegenerative disorders referred to as
frontotemporal dementia and parkinsonism linked to chromosome
17 (FTDP-17) [11–14]. Important insights from these revelations are
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and that the tau abnormalities alone are capable of provoking
neurotoxicities. A sequential pathway consisting of the Aβ-tau-
neurotoxicity continuum can accordingly be illustrated as the central
scheme in the “amyloid cascade” hypothesis on the AD pathogenesis
[15]. Meanwhile, mice transgenic for the mutant APP or doubly
transgenic for the mutant APP and PS-1 have been shown to develop
behavioral alterations and senile plaques but not display any ex-
plicit evidence for tau inclusions and neuronal loss [16–19]. Although
the generation of transgenics overexpressing the wild-type or FTDP-
17 mutant tau has led to the demonstration of tau-induced mas-
sive neuronal death in mice [14,19–25], the mechanistic inter-
mediates between tau aggregation and neurotoxic injuries are yet to
be elucidated.
Biomolecular interactions putatively involved in neurological
conditions are currently assessable with multiple analytical modali-
ties exempliﬁed by biochemistry and immunohistochemistry. Since
most of these technologies examine homogenized or thin-sliced
tissue samples, the amount and structural conformation of truly
“bioactive” molecules accessible to the interactants in living brains
may not be accurately monitored. In addition, numbers of molecular
dialogs and signaling take place at a low concentration far below
1 µM, precluding precise nonlabeling detections of these events. To
date, neuroradiological technologies with a high spatial resolution are
applicable to small laboratory animals, and offer a characterization of
in-vivo statuses of pathophysiological elements existing at nM and pM
levels. Positron emission tomography (PET) in particular is suitable
for near-simultaneous targeting of different nervous system mole-
cules, as a wide variety of low-molecular-weight organic compounds
decorated with positron-emitting nuclides (11C, 13N, 15O, 18F, etc.) can
be synthesized without modifying their original chemical structures,
providing decent ﬂexibility in designing imaging agents [26]. Rapid
radioactive decays in these isotopes (e.g. T1/2∼20 min for 11C) are
also advantageous in serially capturing distinct targets with a short
interval. Moreover, the capability of PET scans in evaluating
biologically accessible modes of brain components has been indicated
in recent studies showing that cell-surface, neurotransmitter-attach-
able neuroreceptors can be visualized together with or separately
from internalized forms by using two speciﬁc radioligands with
different cell-membrane permeabilities [27,28].
Despite the lack of deﬁnite evidence, several neuromolecular and
neurocellular alterations downstream of the amyloid ﬁbrillogenesis
have been highlighted in the neurodegenerative cascade as critical
steps linking the gain of neurotoxicities by these ﬁbrillar assemblies to
the loss of neuronal functionalities (left panel in Fig. 1). PET in
conjunction with an array of radiochemical probes enables an
exhaustive tracking of these key processes and their interrelations.
In rodents, this monitoring is performable parallel to genetic and
pharmacological interventions in amyloid formation and other
pathogenic changes, in order to clarify whether such therapeutic
regulations are practically effective for suppressing the entire cascade,
and what processes might remain unmanageable, leading to a poor
outcome, in the course of the treatments. These nonclinical data are
immediately translatable to clinical studies, owing to the compatibil-
ity of the PET tracers between small animals and humans. Conversely,
PET observations in human subjects can be used for a side-by-side
comparison with rodent models, and this bidirectionality reinforces
translational research and development as a dynamic cycle.
2. Multispecies PET imaging of amyloidosis: lighting up the
Aβ chronicle
The self-assembly of amyloidogenic molecules occurs on a
common biochemical basis of β-pleated sheet formation, which is a
secondary structure of proteins constituted by intramolecular and
intermolecular hydrogen bonds between particular β-strandsequences. The stack of β-sheets displays a quite uniform geometric
dimension irrespective of constituent molecules, and therefore yields
an X-ray diffraction pattern with a highly preserved 0.47-nm
meridional spacing, corresponding to the periodic interstrand
distance within a β-sheet [29,30]. A group of chemicals identiﬁed as
β-sheet ligands are ﬂuorescent compounds with a long, ﬂat π-
electron-conjugated backbone, which is thought to allow them to
enter the canal-like architecture of amyloid ﬁbrils and cling to the β-
sheet surface [31]. Consistent with this context, the vast majority of
these chemicals exhibit a high afﬁnity for a wide range of in-vitro
amyloid assemblies, including Aβ, tau andα-synuclein ﬁlaments, with
a dissociation constant (KD) and/or inhibition constant (Ki) below
50 nM [32–38]. One might thus infer their applicability to brain
imaging as an all-purpose amyloid probe capturing senile plaques,
neuroﬁbrillary tangles and Lewy bodies (i.e. intraneuronal α-
synuclein aggregates characteristic of Parkinson's disease and de-
mentia with Lewy bodies). Dozens of 11C- and 18F-labeled chemicals
have thereby been generated for visualizing brain amyloidoses
[33,35,39], by trying to determine the chemostructural requirements
in designing neuroimaging agents, such as: (1) reasonably high
lipophilicity as indicated by the log ratio of differential solubilities in
octanol and water (logP) ranging from 2.5 to 3.5, enabling an efﬁcient
plasma-brain transfer of the compound through the blood–brain
barrier (BBB); (2) rapid clearance of target-unbound compounds from
the brain tissue preferably with a half-life around 15–30 min for
yielding a high amyloid contrast; and (3) high selectivity of the
binding to pathological ﬁbrils with minimal nonspeciﬁc attachments
to the myelin and other lipid-rich nervous system elements. Several
classes of compoundswith a compact core structure have been proven
to readily penetrate the BBB, and have consequently been used for
clinical PET studies for demented patients [40–44]. It is noteworthy
that most of these relatively small-sized radiotracers preferentially
bind to senile plaques without high-afﬁnity associations with tau and
α-synuclein aggregates [38,45,46]. Such “Aβ-selective” binding
properties have been well demonstrated in [11C]Pittsburgh Com-
pound-B ([11C]PIB), which is the most intensively investigated
amyloid radioligand due to its superior sensitivity and speciﬁcity in
the detection of Aβ deposits besides the qualiﬁcation of the
aforementioned requirements [39,41,45,47]. Radiochemical binding
assays as well as autoradiographic and PET imaging in APP transgenic
and APP/PS-1 double transgenic mice have also revealed that [11C]PIB
may primarily bind to a selected subset of Aβ aggregates, since there
was only a tiny amount of high-afﬁnity binding components for this
probe in model mouse brains as compared with human AD cases
[48,49]. Notwithstanding the fact that these animals generate
abundant insoluble Aβ peptides exceeding AD levels, [11C]PIB signals
were barely detectable by high-resolution PET scans of their brains.
In consideration of these observations, Maeda et al. applied [11C]
PIB synthesized with a high speciﬁc radioactivity (∼300 GBq/µmol;
5–10 fold of previous achievements) to capture a small number of
speciﬁc binding sites, and reported the ﬁrst successful demonstration
of the age-dependent brain amyloidosis imaged in APP transgenic
mice [50]. The rationale for the high-speciﬁc-radioactivity imaging is
that the use of hotter radiotracers reduces blockage of the binding
sites by nonradioactive competitors, leading to an improved contrast
of target signals against nonspeciﬁc backgrounds. There was also
considerable diversity in the amount of speciﬁcally bound [11C]PIB
among transgenic strains (Fig. 2A). Indeed, amyloid-associated
radiosignals were noticeable even with a regular speciﬁc radioactivity
approximating 37 GBq/µmol in very old (N25 months) transgenic
mice expressing the Swedish mutant APP under the control of murine
Thy1.2 promoter (APP23 mice), but the binding potential for [11C]PIB
in this transgenic line reached only half of the value in human AD
cortices even at 30 months of age. These data then raised a crucial
issue, namely, the particular composition or conformation of Aβ ﬁbrils
responsible for the constitution of [11C]PIB binding elements. As
Fig. 1. Schematic diagrams of the molecular mechanisms linking brain amyloidoses and symptomatic onset of neurodegenerative disorders. The pathogenic cascade initiated by
amyloid depositions (left) is interconvertible to a network presentation (right), in light of reciprocal causalities between key participants. P1 through P6 denote the magnitude of
each alteration (e.g. amyloid accumulation and reduced cholinesterase activity), and a summation of these changes and their interactions represents the network activity. Ci and Cij
are scaling coefﬁcients. Neuronal death and disease manifestations occur by elevations of this activity beyond thresholds for cellular lethality (TL) and symptoms (TS).
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Aβ heterogeneities primarily comprised of Aβ subtypes ending at
residues 40 and 42, dubbed Aβ40 and Aβ42, respectively, accumu-
lated in an insoluble protein fraction extracted from brains of these
mice. Their levels exceeded those in postmortem AD brains, and
accordingly had no correlation with the radioligand binding.
Moreover, the ratio of Aβ42 to Aβ40, which is markedly low in
transgenics relative to humans [52], did not account for the PET
observations, because transgenic productions of the mutant APP and
PS-1 resulted in an elevated Aβ42/40 ratio [18,51–53] but no overt
enhancement of amyloid PET signals [50]. Hence, there has been no
evidence for the interference between Aβ40 and Aβ42 in the
formation of “AD-like” plaques preferred by [11C]PIB. These indica-
tions have been conﬁrmed by an independently conducted radio-
chemical comparison of PIB binding capacities in aged human and
monkey brains [54], demonstrating that no overt emergence of
binding components for this amyloid probe arises from the deposition
of simian endogenous Aβ40 and Aβ42 identical to human peptides in
an Aβ42-dominant manner. By contrast, heterogeneities in the Aβ N-
terminuswere intimately associatedwith the afﬁnity of PIB, according
to the good spatial agreement of autoradiographic [11C]PIB signals
with the immunoreactivity for an N-terminally truncated and
modiﬁed Aβ termed AβN3pE (Fig. 2B) [50]. A great abundance of
AβN3pE, which begins with pyroglutamated residue 3, was deposited
in AD brains, consistent with earlier ﬁndings [55,56], while the
accumulation of this Aβ subspecies in transgenics was observed at a
relatively low level, and was restricted to the dense cores of amyloid
plaques (Fig. 2B). Unlike AβN3pE, the N-terminal-intact Aβ subtype,
AβN1D, in all transgenic strains examined was accumulated at a level
comparable to AD brains, showing disagreement with the interspecies
and interstrain variabilities in PIB labeling (Fig. 2B). This proﬁle is inline with the PIB-reactivity in the same brain slices, and implies a
pivotal role of AβN3pE in the construction of radioligand binding sites.
Further experiments indicated that the binding capacity for [11C]PIB in
an in-vitro assembly of synthetic AβN3pE peptides was approximately
3-fold that in full-length AβN1D ﬁlaments [50], but these test-tube
results might not fully explain the preferential binding of PIB to
AβN3pE-rich plaques in living brains. The signiﬁcance of the N-
terminal Aβ processing is relevant to the facts that N-terminal Aβ
fragments as well as antibodies raised against N-terminal Aβ
sequences are particularly effective in the immunotherapeutic
removal of senile plaques [57–60], and that vaccination with full-
length Aβ42 generates antibodies against the Aβ N-terminus [61].
Based on these observations, we propose a structural concept that the
N-terminus of Aβ peptides forming the outer surface of amyloid ﬁbrils
[62] confronts contacts by endogenous and exogenous materials, and
therefore determines the accessibility of the β-sheet-layered interior
by these visitor molecules. Since the conversion from AβN1D to
AβN3pE involves a loss of two negative and one positive electric
charges on residues 1–3, AβN3pE ﬁbrils are conceived to possess a
more lipophilic exterior than unprocessed Aβ aggregates [55],
allowing the entrance of brain-penetrable, lipophilic agents exempli-
ﬁed by PIB. Our postulation also brings a view that many endogenous
lipophilic components can dock at the electrostatically neutral
outport of AβN3pE assemblies, yielding a heteromolecular shell
capable of regulating the passage of β-sheet ligands on an electro-
chemical basis. This may also amplify the gain of in-vivo accessibility
to β-sheets through N-terminal Aβ processing beyond the in-vitro
dependency of the PIB binding on Aβ subtypes.
The paucity of AβN3pE in model mice has been biochemically
documented in several reports [52,63], and may be linked to the
relative dominance of two distinct pathways in the Aβ catabolism. The
Fig. 2. Roles of an Aβ subspecies as a major component of “AD-like” plaques preferentially detectable by PET radioprobes. (A) [11C]PIB-PET images illustrating amyloid depositions in
brains of an AD patient (axial view) and different strains of APP transgenic or PS-1/APP double transgenic mice (coronal view) merged onto anatomical MRI maps. Note that the
human andmouse images are differently scaled according to themaximal binding potential for the radiotracer in each species, as indicated by vertical bars. Tg2576mice overexpress
the Swedish mutant APP driven by the hamster prion protein promoter, and PS1/APP double transgenics were generated by crossbreeding Tg2576 mice with A260V mutant PS-1
transgenics. (B) Immunohistochemical assays for N-terminal heterogeneities of Aβ. In the frontal cortex of an AD patient (top panels), both AβN3pE and AβN1D are abundantly
present in diffuse and cored plaques. AβN1D immunoreactivity is also intensely observed in the neocortex of an APP23 mouse, while the localization of AβN3pE in an adjacent
section is conﬁned to the plaque epicenters (middle panels). Despite its paucity, the AβN3pE immunostaining in APP23 mice is well colocalized with [11C]PIB signals (bottom panels;
dual autoradiographic and immunohistochemical labeling).
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and other endopeptidases [64–66], while a small proportion could be
N-terminally truncated by aminopeptidases or dipeptidyl peptidases,
followed by the cyclation of the third glutamate residue presumably
with the aid of glumaminyl cyclase (QC) [67–69]. This enzymatic
manipulation of the Aβ N-terminus is usually overwhelmed by
endopeptidase-mediated degradation, and the uncycled intermedi-
ates lacking the ﬁrst 1 or 2 residues are putatively labile for further
cleavages by endopeptidases. We therefore hypothesize that the
deposition of AβN3pE progresses at a very slow rate, not reaching a
threshold for the massive ﬁbrillization of this Aβ subspecies within 2–
3 years in mice, and within 30–40 years in nonhuman primates. Once
its level passes the critical point, AβN3pE may rapidly aggregate to
pathological plaques, because it is more resistant to peptidases, has
more propensity to self-polymerize, and exerts more cytotoxicity than
AβN1D [70–72]. In light of the time-consuming steps toward its
generation, we consider AβN3pE as an aged Aβ, and accumulations of
total and pyroglutamated Aβ peptides in human brains emerge in a
parallel fashion. Since this “aging of Aβ” indicated by the AβN3pE levelis not recapitulated in rodents and monkeys, they may be models of
disproportionate depositions of total Aβ and AβN3pE.
It subsequently becomes a matter of concern whether [11C]PIB
captures neurotoxic Aβ lesions, provided that AβN3pE ﬁbrils serve β-
sheets accessible by exogenous radioligands. One notable feature of
the [11C]PIB-PET scan in humans is the presence of PIB-positive cases
in the nondemented elderly population, who account for 20–40% of
total subjects aged over 65 years, and develop PIB-positivities with a
prototypical conﬁguration involving the frontal cortex and several
other cortical and subcortical areas [73–75]. A combined histochem-
ical and immunohistochemical examination of autopsied materials
illustrated that non-cored senile plaques without overt dystrophies of
surrounding neurites, referred to as diffuse plaques, are intensely
labeled with PIB, and are enriched with AβN3pE in the frontal region
of human brains (Fig. 2B) [50,56]. This was in sharp contrast with the
concentration of AβN3pE in the dense plaque cores of transgenic
mouse models (Fig. 2B) [50]. We presume that the aggregation of
AβN3pE into diffuse plaques can induce functional deﬁcits in neurons,
according to a recent neuropathological investigation of normal
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assessed by neuropsychological test batteries [76]. Interestingly, the
counts of diffuse plaques and neuroﬁbrillary tangles were correlated
with degraded scores for seemingly distinct cognitive subdomains. In
this sense, [11C]PIB-PET images in the nondemented elderlymay signal
the progress of brain aging to an initial pathological stage, which we
reductionistically interpret at a molecular level as packing of aged Aβ
species represented by AβN3pE in diffuse plaques toward a compro-
mise of neuronal integrities. A recent PET analysis has presented
evidence for a correlation between increased cortical [11C]PIB binding
and impaired episodic memory performance in the elderly [74],
although it is still to be conﬁrmed by further longitudinal neuroima-
ging assessments whether this stage is consecutively connected to the
onset of AD or is merely amechanistic basis of age-associatedmemory
impairments virtually unrelated to AD pathogenesis.
Our second insight from the Aβ metabolism governed by the dual
proteolytic pathways is that a decline in neprilysin activity may
induce increased levels of substrates for N-terminal processing,
eventually resulting in an overproduction of AβN3pE. Hence,
decreased neprilysin levels in the brain as a function of age [77–80]
could underlie pathological brain aging and AD via the neurotoxicity
of AβN3pE. The causal link between deﬁcits of neprilysin and selective
augmentation of AβN3pE deposition has begun to be supported by
our preliminary experiment on APP transgenic mice deﬁcient in the
neprilysin gene, and these bigenic animals have also exhibited
enhanced [11C]PIB signals in the neocortex and hippocampus. As
neprilysin activity is thought to be upregulated by the stimulation of
somatostatin receptors [81], somatostatinergic agents may offer a
pharmacological suppression of AβN3pE, which can be speciﬁcally
monitored by PET with [11C]PIB and other similar radioprobes. It is
also feasible to block the conversion of degradable N-terminally
truncated Aβ intermediates to AβN3pE mediated by the enzymatic
activity of QC, and efﬁcacies of QC inhibitors on the protection of
neurons against AβN3pE toxicity have been demonstrated in APP
transgenicmice [69]. Signiﬁcantly, the amount and activity of QCwere
reported to increase in AD brains possibly for responding to the
overﬂow of its substrate [69], rationalizing the therapeutic targeting
of QC to reverse its activity to a normal level as an anti-amyloid
strategy without pronounced adverse effects. In this way, a series of
basic and clinical studies interconnected through the identiﬁcation
and characterization of in-vivo imaging signals in humans and animal
models have contributed to the mutual facilitation among the
revelation of molecular etiologies and diagnostic and therapeutic
developments.
3. Targeting key holes on tau ﬁbrils with a molecular lockpick
The above-mentioned clinicopathological study of dementia-free
elderly people [76] indicates at least two modes of neurotoxicities
reﬂected by diffuse plaques and neuroﬁbrillary tangles, drawing
attention to the role of ﬁbrillary tau lesions as a winder of the aging
clock in human brains. Additionally, intraneuronal tau inclusions have
been found to more tightly correlate with dementia severity in AD
brains than senile plaques [82,83]. The pathologically enhanced
incorporation of tau proteins into self-aggregates is also inevitably
accompanied by a loss of normally functioning tau species, eventually
disrupting the dynamics and statics of axonal cytoskeletons, because
tau proteins are microtubule-associated components in charge of
promoting the assembly of axonal tubulins into microtubules and
stabilizing tubulins in their polymerized form [14]. These items of
evidence give rise to the idea that either distinct or synergistic
involvements of Aβ (presumably AβN3pE) and tau deposits in
neuronal dysfunction can be mapped by using a radioligand for tau
ﬁbrils in combinationwith a plaque tracer. This techniquemay also aid
the diagnostic differentiation between AD and non-AD tauopathies
based on the presence or absence of amyloid plaques and the spatialdistribution of tau aggregates. In the pursuit of a mechanistic pathway
that connects tauﬁbrillization to neurodegenerative changes, to clarify
the chronological order of the generation of primitive and mature tau
ﬁlaments and neuronal deﬁcits in living humans bymeans of tau scans
in conjunction with functional and morphometric neuroimaging tests
is an issue of particular interest. This time course could also be
captured in transgenic mouse models of tauopathies, and neuronal
death and behavioral phenotypes in different transgenic strains have
indeed been proven to result from the emergence of early-phase tau
assemblies rather than complete neuroﬁbrillary tangles [22–24].
However, it should be noted that the excessive expression of
transgenic products might artiﬁcially provoke neurotoxicities at a
premature stage of tau pathogenesis without any loss of functions of
endogenous murine tau molecules, which need to be compared with
putative mechanisms underlying tau-triggered neurodegenerative
injuries in humans identiﬁable by imaging-based biomarkers.
The development of imaging agents preferentially binding to tau
ﬁbrils could be initiated by screening known and potential β-sheet
ligands, but structural determinants of the selective afﬁnity for tau
aggregates remain elusive. We could conceive that tau ﬁlaments, the
outer layer of which is electromicroscopically characterized as a
diffuse coat and is formed by an alignment of densely charged N- and
C-terminal portions of tau molecules [84,85], are accessible by less
liphophilic agents than are AβN3pE amyloids, bearing a chargeless
surface and allowing contacts by lipophilic probes. It should also be
considered that the equatorial spacing of amyloid ﬁbrils reﬂecting the
intersheet distance in X-ray diffraction assays is somewhat divergent
and is largely affected by the component side chains, unlike the
rigorous conservation of the 0.47-nm meridional spacing [30].
Interestingly, an FTDP-17 mutant tau protein was reported to
aggregate in a test tube at an equatorial spacing of 1.3 nm, which
was considerably longer than the usual value ranging from 1.0 to
1.1 nm [85]. Hence, our current theoretical view is that chemicals with
a longer backbonemight gain a high afﬁnity for tau ﬁbrils by acquiring
the ability to cross-bridge two adjacent β-sheets. This possibility is
supported by the fact that β-sheet ligands with a relatively long frame
(N1.3 nm), such as thioﬂavin-S and X-34 analogs, tend to prefer
neuroﬁbrillary tangles and neuritic/cored plaques to diffuse plaques,
although the determination of structure–selectivity relationships in
an extensive group of tau and Aβ probes is an ongoing issue. Notably,
all established β-sheet tracers bind tightly to the epicenter of dense-
cored plaques, impeding the designing of pure ligands for tau lesions.
A joint use of imaging agents leaning to Aβ and tau lesions would
accordingly be required for extracting spatial maps of ﬁbrillar tau
pathologies.
Compelling proof of a direct interaction between intracellular tau
inclusions and exogenous ligands might be revealed by comparative
in-vivo and ex-vivo imaging assays with the use of animal models
developing tangle-like tau aggregates. Ex-vivo labeling of tau ﬁbrils
with an intravenously injected X-34 analog was actually demonstrat-
ed in a transgenic mouse strain dubbed PS19 (Fig. 3) and similar mice
expressing the P301S FTDP-17mutant tau gene [86,87], validating the
notion that BBB-permeable β-sheet ligands can penetrate neuronal
cell membranes as well. The X-34 family may not fulﬁll the kinetic
criteria for optimal PET tracers [89], while agents with faster tissue
uptake/clearance rates are presently under development for PET
imaging purposes. Putative and potential PET probes for AD
neuroﬁbrillary tangles with more compact chemical structures have
also been reported, as exempliﬁed by [18F]FDDNP [89,90] and [11C]BF-
158 [35]. However, they do not ﬁrmly bind to non-AD tau inclusions,
such as Pick's bodies in Pick's disease, neuronal and glial ﬁbrillary
tangles in progressive supranuclear palsy and corticobasal degener-
ation, and ﬁbrillar lesions in tau transgenic mice, and therefore ex-
vivo and in-vivo evidence for the binding of these compounds to tau
deposits may not be provided by animal models. This is in contrast
with labeling of both AD and non-AD tau pathologieswith thioﬂavin-S
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designing a versatile tau tracer with afﬁnities for diverse tau
aggregates. The difference in acceptable ligands between AD-type
tangles and other tau inclusions also suggests conformational
distinctions stemming from incorporations of all six tau isoforms in
the former versus less than three isoforms in the latter. In terms of tau
isoform compositions, most tau transgenic animals, which have been
generated with a transgene construct coding a cDNA sequence of a
single tau isoform, might be incomplete models of in-vivo tau
ﬁbrillogenesis and tau-induced neurodegeneration, although it is
unclear whether the conformational heterogeneity of tau assemblies
affects their neurotoxicities.
Emerging tau imaging techniques would also be allied with anti-
tau treatments in order to allow translational and clinical proof-of-
mechanism studies on the therapeutants. Since hyperphosphoryla-
tion of tau proteins is characteristic of tauopathies [92–94], inhibitors
of kinases responsible for tau phosphorylation have been developed
and aimed at halting tau pathogenesis [95]. The phosphorylation of
tau proteins diminishes their ability to bind to microtubules [96–98],
disrupting the axonal cytoskeletal stability and presumably promot-
ing the concentration of free tau molecules prone to self-aggregate.
The efﬁcacy of drugs counteracting tau phosphorylation could thereby
be examined by monitoring tau depositions with the assistance of
radioligands for ﬁlamentous tau lesions [95]. In view of the
redundancy of tau-phosphorylating enzymes (e.g. glycogen synthase
kinase 3β [99], cyclin-dependent kinases 2 and 5 [100,101] and
mitogen-activated protein kinase [96,102,103]), we infer that the
pathologies of phosphorylated tau proteins might not be highly
responsive to the pharmacological suppression of a single kinase,
while a full blockage of this enzyme may impair physiological
functions of its more speciﬁc substrates.
Therapeutic interventions in tau pathogenesis would also be
enabled by inhibiting the self-polymerization of tau molecules into
ﬁbrils, as indicated by previous in-vitro and in-vivo experiments using
organic chemicals [104–110]. A signiﬁcant subset of these anti-
aggregation agents are the β-sheet ligands capable of binding to mostFig. 3. Ex-vivo ﬂuorescence labeling of intraneuronal tau inclusions with an analog of X-34
removed at 3 h after the termination of the tracer infusion. A coronal slice containing the
postmortemly-applied antibody against phosphorylated tau (AT8). Areas indicated by whitamyloid ﬁlaments, but they are slightly larger than known imaging
probes for Aβ and tau aggregates. It can be expected that a compound
with sufﬁcient steric bulk may exert effective interference with the β-
sheet formation [111], and appropriate molecular mass and total
surface area of such chemicals could be determined by trade-offs
between their BBB-permeability and anti-aggregation potency. Congo
red was one of the ancestor compounds shown to attenuate the in-
vitro ﬁbrillization of either Aβ or tau [112], and its derivatives, the X-
34 family, retain the ability to suppress the growth of amyloid
ﬁlaments [108,113]. In addition, these bis-styrylbenzene group
members are hitherto the only chemicals proven to bind to
intraneuronal tau inclusions in living brains after being systemically
administered to tau transgenics (Fig. 3) [86,87]. It therefore seems
feasible to design a tau amyloidogenesis inhibitor by structurally
modifying these chemicals, and decorations of them with adequate
side chains may augment their interference with tau aggregation. The
chemical “bodybuilding” using bulky substructures, however, should
be done to such an extent that their transferability through BBB
remains acceptable as a therapeutic drug. Since the X-34 family
exhibits high afﬁnities for Aβ and tau lesions in AD and non-AD tau
inclusions, modiﬁcations of its members would also become versatile
amyloid ﬁlament blockers targeting a wide range of neurodegener-
ative disorders. Although anti-ﬁbrillogenic activities of these inhibi-
tors could be quantitatively monitored with the aid of β-sheet-
binding PET radiotracers, a pitfall in the neuroimaging-based
therapeutic evaluation is that a reduction of in-vivo radiolabeling
may occur as a consequence of either effective removal of tau ﬁbrils or
occupancy of the radioligand binding sites by the test drugs. This
competition might be circumvented by choosing an imaging agent
constituted of a core structure distinct from those of the anti-
ﬁbrillogenics. For instance, thioﬂavin-type benzothiazoles do not
compete with X-34-like bis-styrylbenzenes for in-vitro Aβ assemblies
[88,114], and similar features could be examined for tau ﬁlaments.
Even though certain classes of small molecules display efﬁcacies in
suppressing the formation of high-order tau polymers, there may be a
possibility that less mature species of tau aggregates play essentialdubbed FSB. PS19 mouse was administered with 10 mg/kg of FSB, and its brain was
brain stem displays numerous tau lesions doubly stained with administered FSB and
e squares are presented at a higher magniﬁcation in the bottom panels.
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relevant to the implication of oligomeric Aβ peptides indicated by
multiple lines of cell culture and animal studies [115–118], and to the
observation of a neuronal loss antecedent to thioﬂavin-S-positive tau
inclusion in murine transgenic models [22–24]. From this viewpoint,
nonclinical and clinical validations by visualization of amyloid
depositions parallel to volumetric and/or functional imaging of
neuronal damages are required regarding the beneﬁcial effects of
anti-Aβ and anti-tau aggregation therapies on nervous system
integrities. These research efforts would also shed light on the
neuropathological resemblance of model mice and humans in relation
to the neurotoxicity of oligomeric Aβ and tau, and would open
an avenue to better replicate human pathogenesis in experimental
animals.
4. Surveillance of neuroimmunity — trooping minesweepers
or minelayers?
Accumulating evidence has unraveled an essential part played by
dialogs between neurotoxic amyloidosis and neuroimmune responses
in the evolution of neurodegenerative disorders [119–124]. A
remarkable nature of immunocompetent cells in the brain, repre-
sented by activated microglia, is their strong potency in manipulating
depositions of proteinaceous aggregates. Aβ immunotherapies stim-
ulating neuroprotective microglia have been shown to effectively
eliminate amyloid plaques [58–60,121,123,125–129], and are cur-
rently in a clinical trial stage. Meanwhile, a recent study on a
tauopathy mouse model, PS19, has revealed an enhancement of tau
abnormalities and neuronal death by toxic microgliosis, which could
be therapeutically diminished by oral administration of an immuno-
suppressant, FK-506 [24]. A substantial amelioration of ﬁbrillar tau
pathologies by systemic treatment with minocycline has also been
observed in ‘humanized’ tau transgenic mice, which overexpress all
six human tau isoforms but lack endogenous murine tau proteins
[130]. Although both FK-506 andminocycline act on neuronal kinases,
phosphatases and multiple other targets apparently unrelated to
immune reactions, it is plausible to attribute the beneﬁcial out-
comes of these drugs primarily to the arrest of the pro-inﬂammatory
activities mediated by a microglial subpopulation. Hence, these inter-
ventions in Aβ and tau pathogeneses sharpen two incompatible
functions of glial cells, leading to either restoration or deterioration
of neurons [131,132]. They also support the assertion that the amyloid
cascade is not a unidirectional pathway but could be partially self-
regulated through positive or negative feedback loops between up-
stream (e.g. amyloidosis) and downstream (e.g. microgliosis) processes.
Substantive research attempts have also enabled the visualization
of microglial activities in living individuals by means of PET and
radiolabeled ligands for translocator proteins (TSPO; also known as
peripheral benzodiazepine receptors). TSPO is an outer component of
mitochondrial permeability transition pores (mPTPs) [133–136], and
its upregulation is known to accompany microglial activations in
response to ischemic, traumatic and chemical brain damages (Fig. 4A)
[137–145]. An initial 11C-labeled TSPO probe, [11C]PK-11195, has been
applied to the assessment of neuroinﬂammatory changes in patients
with neurodegenerative disorders, such as AD and Parkinson's disease
[146–151], as well as experimental models of these illnesses
[152,153]. Despite the observation of elevated TSPO levels in a large
subset of AD patients, several properties of TSPO imaging do not
necessarily represent its utility as a diagnostic marker for AD and
associated diseases. Indeed, a notable variability of TSPO levels in
elderly controls and patients diminishes the discrimination power of
TSPO-PET assays [149–151]. Furthermore, spatiotemporal relation-
ships between TSPO and neurodegenerative amyloidosis seem elusive,
because TSPO signals become intensiﬁed in neocortices, thalamus and
other extensive areas of AD brains without any correlation with the
clinical stage of cognitive impairments [146,149–151]. These data,however, have led us to a new insight into the AD etiology, namely,
that an age-associated neuroinﬂammatory change attended with a
widespread TSPO surge emerges antecedent to or independent of Aβ
and tau depositions, but accelerates these amyloidotic processes once
they are initiated.
The use of laboratory animals has facilitated the development of
second-generation TSPO radioprobes with improved pharmacokinetic
properties. Studies of rodents given neuronal injuries and normal
monkeys proved efﬁcient BBB passage and high-afﬁnity binding to
target sites achieved by groups of chemicals, including DAA-1106
([11C]DAA1106, [18F]ﬂuoroethyl-DAA1106, etc.) [24,50,154–158] and
Ac5216 ([11C]Ac5216, [18F]ﬂuoroethyl-Ac5216, [18F]ﬂuoroethyl-des-
methyl-Ac5216, etc.) [159,160] families. Three of these ligands have so
far been applied to human subjects [161–163], and a comparative PET
analysis of nondemented elderly and AD cases was conducted with
[11C]DAA1106 [164]. The high-contrast TSPO images in this [11C]
DAA1106-PET assay [164] brought an explicit indication that the
subglobal TSPOupregulation observed in [11C]PK-11195-PET studies is
reproducible with different tracers and analytical methods. Research-
ers then revisited small animals to assess whether TSPO-positive glia
are diffused or tightly associated with Aβ and tau aggregates in the
presence of AD-like pathologies. Autoradiographic and PETmapping of
APP23 and PS19 mice with the use of tritiated and 18F-ﬂuorinated
DAA1106 illustrated the localization of TSPO signals conﬁned to the
proximity of Aβ plaques and intraneuronal phospho-tau deposits,
respectively, in contrast to the outcome of clinical PET studies (Fig. 4B)
[24,158]. Thus, multiregional activations of TSPO-expressing glial cells
in humans, which we assume to be in concurrence with pathological
brain aging and to worsen the tissue vulnerability to amyloid-induced
toxicities, are not recapitulated in the existing mouse models of AD.
The lack of diffusely increased TSPO signals, however, renders
these mice useful for highlighting the local crosstalk between glia and
AD amyloidosis. Interestingly, immunohistochemical data have
shown that plaque lesions in APP23 mice are encompassed by
TSPO-positive astrocytes and TSPO-negative microglia, presenting a
prominent contrast to microglia-dominant TSPO expressions induced
by the phospho-tau accumulation in PS19 mice [158]. Our pilot
investigation of autopsied brain samples has supported a microglial
but not astrocytic induction of TSPO immunoreactivities in AD brains,
and implies that the TSPO-positivemicroglia observedmay be actively
involved in neurotoxic insults, giving rise to amassive neuronal loss in
PS19 mice (Fig. 4B) and AD patients. Unlike these neurodegenerative
devastations, no or minimal neuronal death takes places in APP23 and
many other APP transgenics [165–167], and we accordingly hypoth-
esize that activations of TSPO-positive astrocytes and TSPO-negative
microglia could be linked to the neuritic and synaptic regeneration in
the vicinity of plaques as noted in these animals [168]. These views
were consistent with indications in other models of neurodegener-
ative insults, represented by TSPO-expressing microglia contacting
unrecoverably damaged neurons in kainate-triggered excitotoxicity
and ethanol-induced necrotic injuries, versus clustering of TSPO-
positive astrocytes and TSPO-negative microglia in the spontaneous
recovery from demyelinating conditions following treatments with
cuprizone (Fig. 4C) [158]. Demonstrations of neurotrophic supports
by TSPO-positive astrocytes were further supplemented by correla-
tions of TSPO and glial cell line-derived neurotrophic factor expres-
sions in activated astrocytes responding to these model pathologies
[158].
There appears to us a possibility that an elevated TSPO level beyond
a certain threshold is interconnected to the conversionofmicroglia to a
neurotoxic form. Hence, amyloid-provoked TSPO increase may easily
top this threshold in human cases, if theirmicroglia in advance express
a decent amount of TSPO in extensive brain areas. It is similarly likely
in our view that Aβ immunization in AD patients drives microglia to a
hyperactive state featured by a TSPO rise,making a detrimental impact
on tau pathologies and neuronal survival. As increased TSPO signals in
Fig. 4. Detection of neuroinﬂammatory responses by imaging agents for TSPO. (A) Composition of mPTP in resting (top) and activated (bottom) glial cells. TSPO is located on the
outer membrane (OM) of mitochondria, and is supposedly intensiﬁed in a polymeric form upon glial activations. Another outer element, voltage-dependent anion channel (VDAC),
and inner-membrane (IM) component, adenine nucleotide translocator (ANT), constitute a channel structure allowing transports of selected molecules, and receive excitatory and
inhibitory controls by pro-apoptotic Bax and antiapoptotic Bcl-2, respectively. Hexokinase II (HK II) and cyclophilin D (Cyp D) are also structurally and functionally coupled with
these translocators. (B) In-vivo T2-weighted MRI and [18F]ﬂuoroethyl-DAA1106-PET scans of wild-type and PS19 mouse brains. The hippocampus, outlined by dots, exhibits
pronounced atrophy and increased TSPO levels in PS19 mice. (C) Two distinct modes of the interplay between glia and injured neurons characterized by TSPO expressions. In case of
recoverable damages, TSPO(−) microglia and TSPO(+) astrocytes act for neuronal repairs. Irreversible insults leading to neuronal death are featured by activations of TSPO(+)
microglia and TSPO(−) astrocytes.
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demonstrated by PET and [18F]ﬂuoroethyl-DAA1106 [50], in-vivo TSPO
imaging techniques would allow the maintenance of microglial
activities in an appropriate range during immunotherapeutic
approaches to AD.
The potential limitation of TSPO assays in living subjects may stem
from their incapability of dissociating between microglia and
astrocytes overpresenting TSPO. A high-throughput exploration of
molecules speciﬁcally existing in TSPO-positive and TSPO-negative
microglia could be targets in differential visualizations of aggres-
sive and neuroprotective microglia. Toward this aim, experimental
transplantation of cultured microglia producing TSPO at low and high
levels into brains of model mice could be performed, and correlations
of their in-vivo functions with microglial components are assessable
by a combination of antemortem neuroimaging and postmortem
biochemical examinations.
In addition to its signiﬁcance as a visible biomarker, TSPO may
pivotally contribute to the switching of glial characters, and can be
targeted by therapeutic ligands. As aforementioned, TSPO is a major
constituent of mPTPs (Fig. 4A), but its roles beyond the trafﬁcking of
intracellular cholesterols related to the neurosteroid synthesis are
generally unknown. The opening of mPTPs promotes abolishment of
the mitochondrial membrane potential, leading to either mitochon-
drial autophagy or necrotic and apoptotic cell deaths [169–171].
Moreover, exposure to excessive oxidative stresses gives rise to the
opening of mPTPs and consequent collapse of mitochondrial mem-
brane potential. This in turn reinforces the generation of reactive
oxygen species (ROS) and its release into the cytosolic compartment,causing an intermitochondrial transmission of ROS waves [172,173].
Thus, TSPO is presumed to eventually participate in the regulation of
glial vitality and ROS-mediated glial toxicity. It has been documented
that the conventional knock-out of TSPO in mice is lethal [174], im-
plying the need for the generation of animals conditionally deﬁcient
in microglial and/or astrocytic TSPO for the pursuit of its pathophys-
iological roles. Parent chemicals of some TSPO imaging probes are
known to act as anti-anxiety and anti-depressant drugs [175–178],
putatively by modulating mitochondrial functions in the nervous
system cells, and would be structurally optimized for the purpose of
“glial rehabilitation”, which mends glial proﬁles from deleterious to
beneﬁcial toward the protection of neurons against amyloid-initiated
injuries.
5. Unskippable intermediates, functional deﬁcits, cellular lethality,
and bi-causality — grasping the recurrent cascade correlations
Besides neuroinﬂammatory responses accompanied by glial
TSPO expressions, a number of other molecular and cellular events
mediating between amyloidogenesis and neuronal death in the
neurotoxic cascade are potentially targetable by imaging and
disease-modifying agents, which are often structural derivatives of
each other. Quite a few researchers support the view that oligomeric
or polymeric assemblies of Aβ disrupt the intraneuronal calcium
homeostasis via several proposed mechanisms such as induction of
membrane lipid peroxidations inhibitory for ion-motive ATPases
[179,180]. Aberrantly elevated levels of cytoplasmic calcium ions
activate calcium-dependent cysteine-proteases, calpains, which
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of cyclin-dependent kinase 5 in a deregulated manner, phosphoryla-
tion of tau proteins by this kinase may be markedly accelerated.
Calcium mistrafﬁcking and calpain upregulation thus link Aβ and tau
abnormalities, and immunohistochemical assays have revealed
activation of calpains by a self-cleavage in AD brains [183,184]. In-
vivo models represented by mice transgenic for and deﬁcient in an
endogenous calpain-inhibiting protein, calpastatin, have permitted
investigation of calpain-mediated neuropathologies [185,186]. An
injection of kainic acid into brains of these animals demonstrated
roles of calpains in both cytoskeletal disorganization involving tau
phosphorylation and overdrive of pro-apoptotic signals [185,186].
Participation of calpains in synaptic dysfunctions has also been proven
in APP/PS-1 double transgenic mice, as treatments with low-
molecular-weight calpain inhibitors reversed perturbation of long-
term potentiation (LTP) and behavioral deﬁcits in these mice [187].
This study has also raised the possibility of generating imaging probes
for calpains derived from inhibitory compounds. The present
mainstream strategy for the development of calpain inhibitors is
based on the incorporation of P1 and P2 residues of the substrates
[188], but these peptidyl derivatives may not undergo trans-BBB
delivery sufﬁcient for visualization of calpains in living brains. To date,
the crystal structure of calcium-bound calpains interacting with
calpastatin has been identiﬁed [189], and would bring insights into
new classes of synthetic chemicals reactivewith active calpains bound
to calcium.
Pathological consequences of Aβ and tau aggregation may also
converge on mitochondrial disturbances. The integrity of this
organelle is maintained by its axonal transport supported by normally
functioning tau proteins, and retarded movements of fast (e.g.
organelles) and slow (e.g. neuroﬁlaments) transport components
along the axon have been observed in multiple tau transgenic strains
[14,20,190]. In addition, an entrapment of swollen mitochondria in
cytoplasmic tau ﬁbrils is ultrastructurally illustrated in PS19mice [24].
On the other hand, access of Aβ peptides to an inner component of
mPTP, cyclophilin D (Fig. 4A), has been implicated in AD, and APP
transgenicmice lacking cyclophilin D have exhibited alleviation of ROS
overproduction and mitochondrial dysfunctions, leading to improve-
ments of LTP and behavioral phenotypes [191]. As described earlier,
the opening of mPTP diminishes mitochondrial membrane potentials
triggering a cell death signaling pathway [169,170]. This process is also
augmented by a release of cytochrome c through mPTPs, which is
subject to coupling with apoptotic protease-activating factor 1 and
resultant activation of caspases [192]. Interventions in mPTP-mediat-
ed cellular insults could accordingly be a central focus in therapeutic
controls of the neurodegenerative cascade, and monitoring of mPTPs
with a speciﬁc probe is an urgent requirement. Radioligands of TSPO
may help meet this demand, if enhanced recruitment of TSPO into the
pore complex is concurrent with the mPTP activation. TSPO has been
believed to be exclusively localized to glial lineages in the brain, yet its
expression in neuronal cells is under investigation by our research
group. Moreover, imaging agents for cyclophilin D would enable
assessments of mitochondrial deteriorations in a diseased condition,
because levels of this molecule are reportedly elevated in AD brains
[191]. Although several organic compounds, including cyclosporin A,
exert antagonism to cyclophilin D [193], these ring-shaped polypep-
tides may not enter brain tissue with high efﬁciencies, impeding the
application of their radiolabeled analogs to in-vivo mapping of
cyclophilin D and mPTPs.
At the bottom of the hierarchy in the amyloid cascade exist
disordered neurotransmissions and neuronal death, yet they are of
prime importance in the mechanisms of symptomatic manifestations.
It is also noteworthy that dysregulation of the neurotransmitter
systems may in turn aggravate the intermediate processes, as
exempliﬁed by a compromised calcium homeostasis attributable to
activations of ionotropic glutamate receptors [194,195]. The predictedsigniﬁcance notwithstanding, there have been no radioligands
suitable for PET imaging of these receptors. The majority of
antagonists for glutamate and glycine binding sites on N-methyl-D-
aspartic acid (NMDA) receptors possess more than one charged
moiety [196], hampering their entries into the brain. Electrically
neutral quinolone derivatives have shown afﬁnities for glycine
binding sites, and their 11C-labeled versions have been applied to
animal and human assays [197–199]. Contrary to expectations, the
brain uptake of these probes was not satisfactory for detecting subtle
changes in pathological conditions, putatively due to their tight
binding to plasma albumin and their property as substrates for P-
glycoprotein (Pgp) efﬂux pump expressed on the luminal surface of
cerebral endothelial cells [199]. The functional BBB against glutama-
tergic agents formed by Pgp well indicates the elaborate protection of
the brain from exogenous components likely to jeopardize neuronal
functionality and survival. Taking a lesson from these results,
designing and characterization of PET imaging ligands for NMDA
and other types of ionotropic glutamate receptors are still ongoing.
As a matter of fact, clinically approved and in-development drugs
for symptomatic treatments of AD are chemicals acting on speciﬁc
neurotransmitter systems [200], which may also display abnormal-
ities in transgenic models of brain amyloidoses. A volume of literature
has documented cholinergic deﬁcits in APP23 and other APP
transgenic and APP/PS-1 bigenic mice [201–204]. Importantly, a
recent biochemical study has indicated that acetylcholinesterase
(AChE) and choline acetyltransferase activities are signiﬁcantly
reduced in the basal forebrain nuclei of APP23 mice, prior to the
emergence of plaque lesions in the neorcortical and hippocampal
regions [203]. This observation suggests the possibility of capturing
cholinergic impairments in prodromal AD cases by a radioprobe
before they become positive for amyloid PET tests. Several PET tracers,
such as radiolabeled substrates [205,206] and inhibitors [207] for
AChE, have revealed a profound reduction of this enzyme in AD
patients, but clinical data have seemingly supported the superiority of
[11C]PIB-PET to AChE imaging in detecting early pathological altera-
tions, judging from the presence of PIB-positive subjects even in
nondemented elderly populations [73–75] versus no overt age-
related changes in AChE levels [206,208]. Of course, this might be
due to difﬁculties in spotting slight irregularities of the cholinergic
system initiated in a small anatomical structure by means of PET
scans. To assess the in-vivo detectability of cholinergic deﬁciencies,
comparative PET, biochemical and immunohistochemical examina-
tions of the cholinergic elements in animal models would be required.
While cholinergic neurotransmission appears particularly vulnera-
ble to the Aβ-triggered neuronal insults, other modalities, including
monoaminergic and glycinergic systems, may also be affected by an
incipient toxicity, as proven by the above-referenced study [203].
Furthermore, the formation of ﬁbrillary tau inclusions is likely to
promote synaptic disruptions independently of or synergistically with
pathological Aβ species. Our pilot PET imaging has shown a severe loss
of serotonin 1A receptors in the hippocampus of PS19 mice with
occurrence of atrophies in this region (Fig. 5A), and younger mice are
currently being tested to verify the possibility that serotonergic
damages precede neuronal death. This ﬁnding raise the possibility
that the serotonin neurotransmission is susceptible to tau abnormali-
ties, and could offer a mechanistic explanation for depressed levels of
hippocampal serotonin 1A receptors in ADbrains documented in recent
clinical PET studies [209,210].However, implicationsof these alterations
in serotonergic components in cognitive and psychiatric manifestations
remain to be determined. The identiﬁcation of susceptible neurotrans-
missions would offer a sensitive determination of whether therapeutic
regulations of the cascade top with anti-amyloid agents can ameliorate
the bottom events featured by such synaptic dysfunctions, and
eventually clarify whether the unidirectionality or bidirectionality of
causalities governs the amyloid cascade. As pathogenic molecules in
transgenics are often expressed under the control of heterologous
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voked impairments might not be identical to those selectively
vulnerable to endogenous Aβ and tau accumulations in humans. A
comparison of neurotransmission PET data across different transgenic
strains and humans would address this issue, and would deﬁne the
validity of these animals as models of AD-characteristic synaptic
injuries.
It should also be noted that the intensity of radioligand signals,
convertible to kinetic parameters such as binding potential and
metabolic rate, may not necessarily reﬂect the amount of target
neurotransmission components, but can be inﬂuenced by their
(subcellular) translocation, posttranslational modiﬁcations (phos-
phorylation, etc.) and coupling with their endogenous orthosteric andFig. 5. (A) Structural MRI and PET imaging of serotonin 1A receptors using a high-afﬁni
hippocampi (outlined by dots) indicate striking atrophy and serotonergic dennervation in
neurotransmitters (right). The radiotracer binding sites are competitively displaceable by th
microdialysis samples obtained from rat striata. A surge of DA by 10-fold of baseline is induc
pretreatment with an antagonist for metabotropic glutamate receptor 5, termed MPEP. (D)
assays. The binding of agonistic DA D2 receptor radioligand, [11C]MNPA, is noticeably blo
administration of MPEP prior to the MAP challenge.allosteric ligands [211]. The occurrence of endocytotic internalization
of receptors and transporters can be indirectly probed by using two
radioligands with different cell-membrane permeabilities [27,28].
Altered levels of synaptic neurotransmitters are also measurable as
changes in the concentration of speciﬁcally bound radioligands due to
competitive inhibitions, provided that the afﬁnity of the radiolabeled
probes is in an adequate range so that their binding can be displaced
by the neurotransmitters with relative ease (Fig. 5B) [211]. As
demonstrated by visualization of dopaminergic overﬂows by amphe-
tamines, agonistic rather than antagonistic agents may sufﬁce the
purpose of sensitively detecting the neurotransmitter release and
depletion, because of their selective binding to agonistic binding sites
displaceable by endogenous ligands [212–215]. These studies havety radioligand, [11C]WAY-100635, in wild-type and PS19 mice. Coronal views of the
the transgenic. (B) Availability of neuroreceptors at baseline (left) and overﬂow by
ese endogenous ligands. (C) Extracellular dopamine (DA) concentrations measured in
ed by intravenous injection of methamphetamine (MAP), and is strongly suppressed by
PET scans of a conscious rat in experimental conditions identical to the microdialysis
cked by endogenous competitors following MAP injection. This effect is reversible by
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timulant yielded a 20% reduction in agonistic radioligand binding
(Fig. 5C and D), raising the concern that pathophysiological ﬂuctua-
tions of synaptic neurotransmitter concentrations, being putatively
milder than pharmacological modulations, might not be detectable by
PET scans with a test–retest variability of 5–15%. It is thus
indispensable to verify the in-vivo measurability of such alterations
using combined PET and microdialysis assays in animals (Fig. 5C and
D) [215]. Importantly, the trans-BBB delivery, clearance and speciﬁc
binding of radioligands for neurotransmission elements are sensitive
to the use of anesthetics, and scanning of unanesthetized animals
(Fig. 5D) may markedly contribute to an improvement of intra- and
inter-subject reproducibility [215]. As this experimental procedure is
now applicable to mice, functional viabilities of the neurotransmitter
systems in the course of amyloid-induced pathologies and their
therapeutic reversals would be noninvasively investigated in trans-
genic disease models by neurotransmission PET scans following
pharmacological and non-pharmacological stimulations.
The total magnitude of neuronal damages irrespective of neuro-
transmitter types is measurable by glucosemetabolic PET imaging and
volumetric magnetic resonance imaging (MRI) [216]. Metabolic scans
using PET and [18F]ﬂuoro-deoxy-glucose ([18F]FDG) in principle
reﬂect both loss of synaptic energy consumptions and death of
neurons [217], and is conceivably advantageous over MRI in probing
brains for synaptic deteriorations antecedent to the neuronal decline.
However, loss of inhibitory synapses leads to a disinhibition of
excitatory neurons, which might partially rebound the metabolic
drop. In addition, increased glucose utilization by growing astrocytic
and microglial populations in response to tissue damages could
incompletely cancel the hypometabolic state. These factors possibly
provide an accountable reason for the fact that well-calibrated MRI
volumetry is equivalent or somewhat superior to [18F]FDG-PET in
terms of the precision of a two-point longitudinal test for separation
between AD and controls [218]. In rodent experiments, high-ﬁeld MRI
devices permit a topographic analysis of living brains with a spatial
resolution below 50 µm [219]. Such detailed mapping provides a
remarkable beneﬁt in detecting atrophies of tiny structures as
compared with small animal PET with a spatial resolution approxi-
mating 1.3 mm [220], particularly in case pathological changes take
place unevenly among brain subregions. The metabolic rate for
glucose is variable as a function of the anesthetic depth [221], and this
effect may display regionality. Similar to selective neurotransmis-
sion PET mapping, [18F]FDG-PET and MRI are of potential utility in
determining whether the therapeutic effects of anti-amyloid agents
can penetrate the pathological cascade pathway toward a suppression
of neuronal lethality, or are faded by inverse causalities from down-
stream to upstream events.
6. Concluding remarks
The concept of the amyloid cascade has lately been updated by the
nonclinical evidence that a topical administration of Aβ oligomers has
adverse impacts on LTPs and behavioral test performances in rats
[116–118], supporting the presence of a direct pipeline between Aβ
aggregation and disordered neurotransmissions. However, little is
known as to whether this shortcut leads to neuronal death and
disease onset, and we conceive that tangled network of mutual
mechanistic links among diverse key processes is still paramount in
the neurodegenerative etiology of AD and allied illnesses (right panel
in Fig. 1). Aβ and tau abnormalities thus have synergistic connections
directly and by way of neuroinﬂammation and other network nodes,
all of which could be stimulated as a function of age. This might
provide a logical explanation for the pathogenesis of sporadic plaque-
negative tauopathies and the lack of intense tau inclusions in APP
transgenic models. Therapeutic monitoring backing onto unraveling
of this webbed cascade should accordingly track these multiple stepsin order to identity treatment-resistant, self-amplifying cycles formed
by two interpromoting processes. The commencement and reinforce-
ment of the cascade may be efﬁciently arrested by simultaneously
overturning more than two processes with co-administered agents
counteracting individual pathological events. This approach would
permit a synergistic use of drug candidates, each of which alone may
not be potent enough to suppress the entire cascade, and would give a
second chance to dropouts in the research and development stages. A
critical notion highlighted by these insights is that neurodegenerative
disorders in a mechanistic sense are not disorders but “pathological
orders” of autonomic signaling networks architected in the cascade.
This inevitably claims a systemic order of diagnostic and therapeutic
strategies targeting manifold key steps, and time-course imaging
studies of multigenic mice generated by crossbreeding of elemental
models should crucially contribute to the elucidation of the network
dynamics.
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